Each additional incorrect answer by older adults on an odor identification test increased all-cause mortality risk by 6% over 6 years, according to a recent study.
Each additional incorrect answer by older adults on an odor identification test increased all-cause mortality risk by 6% over 6 years, according to a recent study.
A clinical trial that investigated the best time within the recommended 14-day window to initiate treatment with a direct oral anticoagulant in patients with acute ischemic stroke with atrial fibrillation found no clearly superior day.
A clinical trial that investigated the best time within the recommended 14-day window to initiate treatment with a direct oral anticoagulant in patients with acute ischemic stroke with atrial fibrillation found no clearly superior day.
High-dose vitamin D reduced disease activity over 24 months in patients with clinically isolated syndrome typical for multiple sclerosis (MS) and early relapsing-remitting MS, according to study results published in JAMA.
High-dose vitamin D reduced disease activity over 24 months in patients with clinically isolated syndrome typical for multiple sclerosis (MS) and early relapsing-remitting MS, according to study results published in JAMA.
A newly developed tool uses algorithms trained on dynamic network models to identify hidden markers of epilepsy from a single routine scalp electroencephalogram (EEG), according to a study published in the Annals of Neurology.
A newly developed tool uses algorithms trained on dynamic network models to identify hidden markers of epilepsy from a single routine scalp electroencephalogram (EEG), according to a study published in the Annals of Neurology.
The US Food and Drug Administration (FDA) has approved tenecteplase (TNKase®), a thrombolytic agent developed by Genentech, for the treatment of acute ischemic stroke (AIS) in adults.
The US Food and Drug Administration (FDA) has approved tenecteplase (TNKase®), a thrombolytic agent developed by Genentech, for the treatment of acute ischemic stroke (AIS) in adults.
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
Mild traumatic brain injury (mTBI) that occurred in the context of psychological trauma was associated with poorer long-term outcomes, including greater posttraumatic stress disorder (PTSD) severity, postconcussive symptoms, and disability.
Mild traumatic brain injury (mTBI) that occurred in the context of psychological trauma was associated with poorer long-term outcomes, including greater posttraumatic stress disorder (PTSD) severity, postconcussive symptoms, and disability.
On Monday, the United States Food and Drug Administration (FDA) approved an adaptive deep brain stimulation (aDBS) technology for people living with Parkinson disease (PD).
On Monday, the United States Food and Drug Administration (FDA) approved an adaptive deep brain stimulation (aDBS) technology for people living with Parkinson disease (PD).
Researchers have developed a model that achieved 93% accuracy in predicting neurologic functional independence after carotid revascularization in patients with acute stroke.
Researchers have developed a model that achieved 93% accuracy in predicting neurologic functional independence after carotid revascularization in patients with acute stroke.
A new clinical guideline from the American College of Physicians (ACP) advises monotherapy for episodic migraine prevention in nonpregnant adults in the outpatient setting. The guideline, published in the Annals of Internal Medicine, provides...
A new clinical guideline from the American College of Physicians (ACP) advises monotherapy for episodic migraine prevention in nonpregnant adults in the outpatient setting. The guideline, published in the Annals of Internal Medicine, provides...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click
